Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits

Highlight

• Tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improved motor and daily living activities in early-stage Parkinson’s disease compared with placebo over 26 weeks.
• Flexible dosing (5-15 mg once daily) was generally well tolerated, with adverse events mostly mild-to-moderate and manageable; nausea, headache, and dizziness were the most common effects.
• The trial showed low incidences of somnolence and impulse control disorders, differentiating tavapadon from traditional D2/D3 agonists.
• Long-term safety and efficacy remain to be established in ongoing extension studies.

Study Background